PDF(Pubmed)
Abstract：
Borderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach. The systematic review included articles published between 2000 and 2023 in the databases: PubMed, EMBASE, and Cochrane. After a detailed analysis of the available publications, we qualified for the systematic review: 28 publications on proto-oncogenes: BRAF, KRAS, NRAS, ERBB2, and PIK3CA, 20 publications on tumour suppressor genes: BRCA1/2, ARID1A, CHEK2, PTEN, 4 on adhesion molecules: CADM1, 8 on proteins: B-catenin, claudin-1, and 5 on glycoproteins: E-Cadherin. In addition, in the further part of the systematic review, we included eight publications on microsatellite instability and three describing loss of heterozygosity in BOT. Molecular changes found in BOTs can vary on a case-by-case basis, identifying carcinogenic mutations through molecular analysis and developing targeted therapies represent significant advancements in the diagnosis and treatment of ovarian malignancies. Molecular studies have contributed significantly to our understanding of BOT pathogenesis, but substantial research is still required to elucidate the relationship between ovarian neoplasms and extraneous disease, identify accurate prognostic indicators, and develop targeted therapeutic approaches.
摘要：
边缘性卵巢肿瘤（BOT）显示出有趣的特征，将其与其他卵巢肿瘤区分开。系统评价的目的是分析BOT中发现的分子变化谱，并讨论其在整体治疗方法中的意义。系统评价包括2000年至2023年在数据库中发表的文章：PubMed，EMBASE,还有Cochrane.在详细分析现有出版物后，我们有资格进行系统评价：28篇关于原癌基因的出版物：BRAF，KRAS,NRAS,ERBB2和PIK3CA,20篇关于抑癌基因的出版物：BRCA1/2，ARID1A，CHEK2,PTEN,4对粘附分子：CADM1，8对蛋白质：B-catenin，糖蛋白上的claudin-1和5：E-Cadherin。此外,在系统审查的下一部分，我们纳入了8篇关于微卫星不稳定性的出版物和3篇描述BOT中杂合性丧失的出版物。在BOT中发现的分子变化可以根据具体情况而变化，通过分子分析识别致癌突变和开发靶向治疗代表了卵巢恶性肿瘤诊断和治疗的重大进展.分子研究对我们对BOT发病机制的理解做出了重要贡献，但仍需要大量研究来阐明卵巢肿瘤与外来疾病之间的关系，确定准确的预后指标，并开发有针对性的治疗方法。
